Genflow Biosciences PLC Results of Annual General Meeting (1221C)
08 Juin 2023 - 11:54AM
UK Regulatory
TIDMGENF
RNS Number : 1221C
Genflow Biosciences PLC
08 June 2023
8 June 2023
Genflow Biosciences Plc
("Genflow" or "the Company")
Results of Annual General Meeting
Genflow (LSE: GENF), a UK-based biotechnology company focused on
longevity and the development of therapies to counteract the
effects of aging and diseases associated with advanced age, is
pleased to announce that all resolutions proposed at the Annual
General Meeting held earlier today were duly passed.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire
Chief Executive +32 477 495 881
-----------------
Clear Capital Markets Ltd
-----------------
Corporate Broker
Andrew Blaylock +44 203 869 6080
-----------------
About Genflow
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno-associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase our understanding of the factors that
control and impact lifespan. Genflow researches, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
-Ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMNKFBQCBKKOAK
(END) Dow Jones Newswires
June 08, 2023 05:54 ET (09:54 GMT)
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024